Recent biomarker research has improved the identification of individuals with very early stages of Alzheimer's disease (AD) and has demonstrated that biomarkers are sensitive for measuring progression in the pre-dementia or mild cognitive impairment (MCI) stage and even pre-symptomatic or pre-MCI stage of AD. Because there are no validated biomarkers in AD, it is important to seek out clinical outcomes that are also sensitive for measuring progression in these very early stages of disease. Clinical outcomes are more subjective and more affected by measurement error than biomarkers but represent the core aspects of the disease and are critical for validation of biomarkers and for evaluation of clinical relevance. Identification of individuals with pre-MCI stages of AD will need to continue to rely on biomarkers, but the identification of individuals with MCI who will progress to AD can be achieved with biomarkers or clinical criteria. Although standard clinical outcomes have been shown to be less sensitive to progression than biomarker outcomes in MCI and pre-MCI populations, non-standard scoring has improved the performance of the Alzheimer's Disease Assessment Scale cognitive subscale, making it more sensitive to progression. Neuropsychological cognitive testing items are optimal for measuring progression in pre-MCI populations, and current research is exploring the best ways to combine these items into a composite cognitive score with maximum responsiveness. In an MCI stage, cognitive, functional, and global items all change, and the best single composite score for measuring progression may involve all of these aspects of the disease. The best chance of success in demonstrating treatment effects in clinical trials will be achieved in a well-defined pre-MCI or MCI population and with an outcome that tracks well with clinical progression over time and with time. A partial least squares model can be used to identify these optimal weighted combinations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506938 | PMC |
http://dx.doi.org/10.1186/alzrt127 | DOI Listing |
J Adolesc Health
December 2024
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
This study aims to determine the effect and equity outcomes of smoking prevention or smoking cessation interventions for children and adolescents involving parents. A systematic literature search was conducted between 24 November 2022 and 27 November 2023 in PubMed, Medline, Web of Science, Embase, PsycINFO, Google Scholar, ClinicalTrials.gov, EU Clinical Trials Register, and the WHO international clinical trials registry.
View Article and Find Full Text PDFJ Perianesth Nurs
December 2024
Department of Surgical Nursing, Nursing Faculty, Ege University, Izmir, Turkey.
Purpose: Health literacy is a complex issue that affects the health outcomes of surgical patients. This study aimed to determine the health literacy of general surgery patients.
Design: A descriptive cross-sectional study.
Am J Orthod Dentofacial Orthop
December 2024
Discipline of Orthodontics, School of Dentistry, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Orthodontics, Sydney Dental Hospital, Sydney Local Health District, Sydney, Australia; Division of Orthodontics, University Clinics of Dental Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address:
Introduction: The dentoskeletal effects of clear aligner treatment (CAT) with Invisalign vs temporary skeletal anchorage device-anchored Sydney intrusion spring (SIS) were compared in consecutively treated growing patients with anterior open bite using cone-beam computed tomography scans.
Methods: Fifteen adolescents treated exclusively with Invisalign, and 14 with SIS (first-phase treatment) were assessed retrospectively. Rigid-wise, voxel-based registration of pretreatment and posttreatment cone-beam computed tomography scans were performed using the anterior cranial base, maxillary plane, and mandibular body as reference regions.
Pol J Vet Sci
December 2024
School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan.
Diet has emerged as a key modulator of the gut microbiota, offering a potential strategy for disease prevention and management. This study investigated the effects of the Prescription Diet Gastrointestinal Biome (GB) on 7 healthy dogs and 16 dogs with chronic gastrointestinal diseases (GI dogs). Our investigation monitored changes in body weight and the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) in 16 GI dogs fed a GB diet.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
December 2024
Department of Immunology, Institute of Biomedical Research Universidad Nacional Autónoma de México, UNAM, 04510 Mexico City, Mexico.
Background: Multiple sclerosis (MS) is a demyelinating, neuroinflammatory, progressive disease that severely affects human health of young adults. Neuroinflammation (NI) and demyelination, as well as their interactions, are key therapeutic targets to halt or slow disease progression. Potent steroidal anti-inflammatory drugs such as methylprednisolone (MP) and remyelinating neurosteroids such as allopregnanolone (ALLO) could be co-administered intranasally to enhance their efficacy by providing direct access to the central nervous system (CNS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!